Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10

Literature DB >> 33257340

Bahaa Abu-Raya¹, Soren Gantt², Manish Sadarangani².

Abstract

Entities: Disease Species

Mesh：

Substances：
COVID-19 Vaccines

Year: 2020 PMID： 33257340 PMCID： PMC7721400 DOI： 10.1503/cmaj.201237-f

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

Keyword Cloud
References

× No keyword cloud information.

12 in total

1. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap.

Authors: Geoffrey A Weinberg; Peter G Szilagyi
Journal: J Infect Dis Date: 2010-06-01 Impact factor: 5.226

2. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.

Authors: Graziano Onder; Giovanni Rezza; Silvio Brusaferro
Journal: JAMA Date: 2020-05-12 Impact factor: 56.272

3. Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic.

Authors: Matthew P Cheng; Todd C Lee; Darrell H S Tan; Srinivas Murthy
Journal: CMAJ Date: 2020-03-26 Impact factor: 8.262

4. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020.

Authors: Neeraj Sood; Paul Simon; Peggy Ebner; Daniel Eichner; Jeffrey Reynolds; Eran Bendavid; Jay Bhattacharya
Journal: JAMA Date: 2020-06-16 Impact factor: 56.272

Review 10. SARS-CoV-2 Vaccines: Status Report.

Authors: Fatima Amanat; Florian Krammer
Journal: Immunity Date: 2020-04-06 Impact factor: 31.745

1. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap.

2. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.

3. Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic.

4. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020.

5. Evaluating new vaccines for developing countries. Efficacy or effectiveness?

6. Mathematical modelling of COVID-19 transmission and mitigation strategies in the population of Ontario, Canada.

7. Projecting demand for critical care beds during COVID-19 outbreaks in Canada.

8. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.

9. COVID-19 vaccine design: the Janus face of immune enhancement.

Review 10. SARS-CoV-2 Vaccines: Status Report.